Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 7
Submit an article Journal homepage
245
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia

Satyen Harish GohilDepartment of Academic Haematology, University College London Cancer Institute, London, UK; ;Department of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Nicola MaciociaDepartment of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Pip PatrickCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Thomas RobertsCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Nicholas CounsellCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Paul SmithCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Laura Clifton-HadleyCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Kate CwynarskiDepartment of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Andrew PettittNorth West Cancer Research Centre, University of Liverpool, Liverpool, UK; View further author information
&
Amit Chunilal NathwaniDepartment of Academic Haematology, University College London Cancer Institute, London, UK; ;Department of Haematology, University College London Hospital, University College Hospital, London, UK; ;National Health Services Blood and Transplant, Watford, Hertfordshire, UKCorrespondence[email protected]
View further author information
 show all
Pages 1730-1733 | Received 10 Jul 2017, Accepted 25 Oct 2017, Published online: 22 Nov 2017

References

  • Maffei R, Colaci E, Fiorcari S, et al. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2016;97:291–302.
  • Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. JCO. 2006;24:5343–5349.
  • Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–5297.
  • Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519–2525.
  • Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997.
  • Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122:734–737.
  • Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:417–423.
  • Mehta RS, Di Stasi A, Hosing C, et al. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014;14:e105–e109.
  • Khouri MR, Jabbour EJ, Gulbis AM, et al. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017;23:1405–1410.
  • Chen CI, Paul H, Snitzler S, et al. An phase 2 study of lenalidomide in combination with oral dexamethasone in previously untreated, symptomatic patients with chronic lymphocytic leukemia (CLL). Blood. 2015;126;4163.
  • Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118:3489–3498.
  • Chen CI, Paul H, Wang T, et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br J Haematol. 2014;165:731–733.
  • Wendtner CM, Hallek M, Fraser GA, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57:1291–1299.
  • Chanan-Khan A, Egyed M, Robak T, et al. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017;31:1240–1243.
  • Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31:584–591.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.